{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T19:06:46Z","timestamp":1709233606540},"reference-count":44,"publisher":"Microbiology Society","issue":"1","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,5]]},"abstract":"<jats:sec sec-type=\"intro\">\n                  <jats:title>Introduction:<\/jats:title>\n                  <jats:p>\n                     <jats:italic>Neisseria meningitidis<\/jats:italic> serogroup B is an important infectious agent in developed countries, including Canada. Infants are particularly susceptible to infection with serogroup B because of immature immune systems, pathogen virulence factors and changing serogroup dynamics in the post-vaccination era. Currently, the Ontario provincial government does not include serogroup B in its routine publicly funded meningococcal vaccination program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Presentation:<\/jats:title>\n                  <jats:p>A formerly well 14-month-old male presented to a tertiary hospital emergency department with fever, minor respiratory problems, diffuse purpuric rash, distended abdomen, tachycardia, and history of one episode of vomiting and melena each. Meningococcaemia was immediately suspected, and he was treated with ceftriaxone, cefotaxime and vancomycin before transfer to a different acute care facility within 12\u200ah. <jats:italic>N. meningitidis<\/jats:italic> serogroup B, sensitive to ceftriaxone and penicillin, was identified in his blood. The patient developed gangrene of the lower legs and underwent bilateral below-knee amputation 8\u200adays post-admission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec sec-type=\"conclusions\">\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>This instance of meningococcaemia with extensive sequelae is an example of the various serious outcomes of meningococcal infection. It provides persuasive reason for routine publicly funded vaccination against <jats:italic>N. meningitidis<\/jats:italic> serogroup B in Ontario.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1099\/jmmcr.0.005017","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T12:12:18Z","timestamp":1448971938000},"source":"Crossref","is-referenced-by-count":2,"title":["Paediatric meningococcaemia in northwestern Ontario, Canada: a case for publicly funded meningococcal B vaccination"],"prefix":"10.1099","volume":"3","author":[{"given":"Vic","family":"Eton","sequence":"first","affiliation":[{"name":"Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond S. W.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Ulanova","sequence":"additional","affiliation":[{"name":"Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada"},{"name":"Lakehead University, Thunder Bay, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"issue":"Suppl 2","key":"jmmcr005017-Adelson1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1007\/BF03403702","article-title":"The embodiment of inequity: health disparities in aboriginal Canada","volume":"96","author":"Adelson","year":"2005","journal-title":"Can J Public Health"},{"key":"jmmcr005017-Aghamohammadi1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-008-9229-9"},{"key":"jmmcr005017-Ammann1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197105000-00004"},{"key":"jmmcr005017-Andersen1","doi-asserted-by":"publisher","DOI":"10.3109\/inf.1989.21.suppl-64.01"},{"key":"jmmcr005017-Andrews1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70341-4"},{"key":"jmmcr005017-Bettinger1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819040e7"},{"key":"jmmcr005017-Bettinger12","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182706b89"},{"key":"jmmcr005017-Canavese1","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.I.01468"},{"key":"jmmcr005017-Carter1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0029-2"},{"key":"jmmcr005017-Crowcroft1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h308"},{"key":"jmmcr005017-Dang1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-202"},{"key":"jmmcr005017-Dashefsky1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80290-X"},{"key":"jmmcr005017-Emonts1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00740-0"},{"key":"jmmcr005017-Galloway1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn228"},{"key":"jmmcr005017-Giuliani1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"jmmcr005017-Gounder1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2015.04.001"},{"issue":"185","key":"jmmcr005017-Jacobsen1","first-page":"214","article-title":"Amputation following meningococcemia. A sequela to purpura fulminans","author":"Jacobsen","year":"1984","journal-title":"Clin Orthop Relat Res"},{"key":"jmmcr005017-Joint1","article-title":"JCVI position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK.","year":"2014"},{"key":"jmmcr005017-Khatami1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.3"},{"key":"jmmcr005017-Kinlin1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn383"},{"key":"jmmcr005017-Law1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-015-0469-6"},{"key":"jmmcr005017-Lee1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000374"},{"key":"jmmcr005017-Le1","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1155\/2009\/871071","article-title":"Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection","volume":"20","author":"Le Saux","year":"2009","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"jmmcr005017-Levi1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0037-1615899","article-title":"Disseminated intravascular coagulation","volume":"82","author":"Levi","year":"1999","journal-title":"Thromb Haemost"},{"key":"jmmcr005017-MacNeil1","first-page":"1","article-title":"Meningococcal disease","volume-title":"VPD Surveillance Manual","author":"MacNeil","year":"2011"},{"key":"jmmcr005017-Masignani1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"jmmcr005017-National1","article-title":"Advice for the use of multicomponent meningococcal serogroup B (4CMenB) vaccine.","year":"2014"},{"key":"jmmcr005017-Neal1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7238.846"},{"key":"jmmcr005017-Ontario1","article-title":"Immunization.","year":"2015"},{"key":"jmmcr005017-Ozkan1","first-page":"69","article-title":"IgA and\/or IgG subclass deficiency in children with recurrent respiratory infections and its relationship with chronic pulmonary damage","volume":"15","author":"Ozkan","year":"2005","journal-title":"J Investig Allergol Clin Immunol"},{"key":"jmmcr005017-Pace1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.062"},{"key":"jmmcr005017-Pathan1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.7.601"},{"key":"jmmcr005017-Public1","article-title":"Invasive meningococcal disease.","year":"2014"},{"key":"jmmcr005017-Read1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60842-4"},{"key":"jmmcr005017-Riordan1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70702-9"},{"key":"jmmcr005017-Robinson1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/pch\/19.2.91","article-title":"Immunization for meningococcal serogroup B: What does the practitioner need to know?","volume":"19","author":"Robinson","year":"2014","journal-title":"Paediatr Child Health"},{"key":"jmmcr005017-Salvadori1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/pch\/16.8.485","article-title":"Meningococcal vaccines in Canada: an update","volume":"16","author":"Salvadori","year":"2011","journal-title":"Paediatr Child Health"},{"key":"jmmcr005017-Sopori1","doi-asserted-by":"publisher","DOI":"10.1038\/nri803"},{"key":"jmmcr005017-Snape1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62194-1"},{"key":"jmmcr005017-Stephens1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"jmmcr005017-The1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70756-X"},{"key":"jmmcr005017-Tu1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.096"},{"key":"jmmcr005017-Tuite1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015493"},{"key":"jmmcr005017-Viner1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70180-1"}],"container-title":["JMM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmmcr\/10.1099\/jmmcr.0.005017?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T19:43:55Z","timestamp":1702669435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmmcr\/10.1099\/jmmcr.0.005017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2,5]]}},"URL":"https:\/\/doi.org\/10.1099\/jmmcr.0.005017","relation":{},"ISSN":["2053-3721"],"issn-type":[{"value":"2053-3721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]}}}